Clinical trial
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Active, not recruiting · Phase 1 · 1 countries · Registry ID NCT07299084
Active, not recruitingPhase 1Interventional
What this study is about
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 70 Years
SexAll
Healthy volunteersNot accepted
ConditionDiabetes Mellitus, Type 2, Overweight, Obesity
Full registry criteria
Inclusion Criteria: * Meet one of the following criteria: * Have type 2 diabetes * Have obesity * Have overweight with at least one health issue related to weight but without type 2 diabetes Exclusion Criteria: * Have a condition that affects how their stomach empties * Have had weight loss surgery * Have type 1 diabetes * Have any major medical conditions or histories that could interfere with the study
Treatments and study arms
Tirzepatide
Drug
Administered SC
Primary outcomes
Percentage of Participants with Lack of Gastric Content Retention Post-Solid Test MealBaseline, Day 171 (at 6, 8, 12, 18 and 24 hours after baseline or Day 170 solid test meal)
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Lilly Centre for Clinical Pharmacology🇸🇬 Singapore, Singapore